Abstract In a WHO report released in Feb 2017, Acinetobacter baumannii has been list as top one of critical antibiotic-resistant “priority pathogens” which is in an urgent need for the new treatment. A. baumannii infections have become increasingly difficult to treat because most isolates are highly resistant to a wide range of antibiotics. With the absent of effective antibiotics, an effective vaccination regimen is urgently needed. We have established a pneumonia mouse model by non-invasive intratracheal instillation with A. baumannii and sepsis model by intraperitoneal injection of bacteria. Intranasal or intramascullar Vaccination both showed 100% protection against A. baumannii infection in pneumonia and sepsis model supported by reduced bacteria burderns, pathology, and reduced proinflammatory cytokine. Intranasal immunization also showed cross protection against different type clinical A. baumannii strains. A successful vaccine against A. baumannii will help us control its infection and overcome the development of multidrug resistance.